Teva Pharma (TEVA) Receives FDA Approval for ProAir RespiClick for Pediatric Asthma Patients Ages 4 to 11 – StreetInsider.com

Teva Pharma (TEVA) Receives FDA Approval for ProAir RespiClick for Pediatric Asthma Patients Ages 4 to 11
StreetInsider.com
“The prevalence of childhood asthma in the U.S. is high, at more than six million patients, and that number continues to rise,” said Dr. Erwin Gelfand, Chairman, Department of Pediatrics at National Jewish Health. “For this young population of asthma

and more »

View full post on asthma – Google News

Webinar Examines Pediatric Asthma Community Paramedic Project, Out-of-Hospital Death Responses – EMSWorld (press release) (blog)

Webinar Examines Pediatric Asthma Community Paramedic Project, Out-of-Hospital Death Responses
EMSWorld (press release) (blog)
In children, asthma is the most common chronic illness. In Indiana, one in 10 children have asthma, and statistics show that 30% of children who have been hospitalized require readmission shortly following discharge. To help combat this trend

View full post on asthma – Google News